Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
NCT00622726
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
150
Enrollment
OTHER
Sponsor class
Conditions
Retinopathy of Prematurity
Interventions
DRUG:
Bevacizumab
PROCEDURE:
Conventional Laser for ROP
Sponsor
The University of Texas Health Science Center, Houston